<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
 <channel>
  <title><![CDATA[BIS Research Inc. - Industry Today]]></title>
  <description><![CDATA[BIS Research Inc. - Industry Today]]></description>
  <link><![CDATA[https://industrytoday.co.uk/profile/1421/rss]]></link>
  <atom:link href="https://industrytoday.co.uk/profile/1421/rss" rel="self" type="application/rss+xml"/>
  <item>
   <title><![CDATA[Global Coronary Microvascular Dysfunction Market is Expanding in Diagnostics and Targeted Therapies – BIS Research]]></title>
   <description><![CDATA[CMD is characterized by chest pain, shortness of breath, fatigue, and exercise intolerance. The condition is particularly prevalent among women and patients with diabetes, hypertension, metabolic syndrome, and non-obstructive coronary artery disease. The CMD market is growing due to increased awareness, improved diagnostic capabilities, and the development of targeted therapeutic solutions.]]></description>
   <link>https://industrytoday.co.uk/health_and_safety/global-coronary-microvascular-dysfunction-market-is-expanding-in-diagnostics-and-targeted-therapies-bis-research</link>
   <guid isPermaLink="false">https://industrytoday.co.uk/health_and_safety/global-coronary-microvascular-dysfunction-market-is-expanding-in-diagnostics-and-targeted-therapies-bis-research</guid>
   <pubDate>Tue, 28 Oct 2025 06:12:25 +0000</pubDate>
  </item>
  <item>
   <title><![CDATA[Nasal Polyposis Market Set for Growth through 2035 – BIS Research]]></title>
   <description><![CDATA[The global nasal polyposis market is on a positive trajectory, with BIS Research projecting continued expansion between 2025 and 2035. Growth in this sector is primarily propelled by the increasing incidence of chronic rhinosinusitis with nasal polyposis (CRSwNP), rising demand for biologic medications, and advances in endoscopic surgical techniques and diagnostic imaging. The market is witnessing significant momentum as new treatment options and precision medicine initiatives become more widely available, supporting better symptom control, reduced recurrence, and enhanced patient quality of life.]]></description>
   <link>https://industrytoday.co.uk/health_and_safety/nasal-polyposis-market-set-for-growth-through-2035-bis-research</link>
   <guid isPermaLink="false">https://industrytoday.co.uk/health_and_safety/nasal-polyposis-market-set-for-growth-through-2035-bis-research</guid>
   <pubDate>Fri, 24 Oct 2025 04:38:49 +0000</pubDate>
  </item>
  <item>
   <title><![CDATA[Mucopolysaccharidosis Market set to grow by 2035 – BIS Research]]></title>
   <description><![CDATA[According to BIS Research, the global mucopolysaccharidosis market is on an upward trajectory, driven by increased diagnosis, evolving therapeutic modalities, and supportive government and NGO initiatives. Enhanced awareness, breakthroughs in gene therapy, and the availability of enzyme replacement therapies are improving patient outcomes and broadening treatment options. The market is expected to continue expanding as pharmaceutical companies and biotech firms invest in next-generation solutions, with a particular focus on addressing neurological symptoms and improving long-term prognosis.]]></description>
   <link>https://industrytoday.co.uk/health_and_safety/mucopolysaccharidosis-market-set-to-grow-by-2035-bis-research</link>
   <guid isPermaLink="false">https://industrytoday.co.uk/health_and_safety/mucopolysaccharidosis-market-set-to-grow-by-2035-bis-research</guid>
   <pubDate>Fri, 24 Oct 2025 04:32:57 +0000</pubDate>
  </item>
  <item>
   <title><![CDATA[Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Set to grow by 2035- BIS Research]]></title>
   <description><![CDATA[The global epidermal growth factor receptor-non small cell lung cancer market is witnessing significant momentum, driven by increased recognition of EGFR mutations’ role in lung cancer and advances in targeted therapy development. EGFR-NSCLC is a subtype of lung cancer characterized by genetic mutations in the EGFR gene, resulting in abnormal cell growth. This market’s growth is supported by a rising prevalence of NSCLC, especially in Asia, and a greater emphasis on early diagnosis and personalized treatment approaches.]]></description>
   <link>https://industrytoday.co.uk/health_and_safety/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market-set-to-grow-by-2035-bis-research</link>
   <guid isPermaLink="false">https://industrytoday.co.uk/health_and_safety/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market-set-to-grow-by-2035-bis-research</guid>
   <pubDate>Fri, 24 Oct 2025 04:19:09 +0000</pubDate>
  </item>
  <item>
   <title><![CDATA[Global Pouchitis Market to Reach New Heights by 2035 – BIS Research]]></title>
   <description><![CDATA[According to BIS Research, the global pouchitis market is entering a phase of sustained expansion, driven by continuous innovation in treatment modalities, growing patient awareness, and rising demand for advanced gastrointestinal care. As clinical understanding and therapeutic options evolve, more patients are being diagnosed and effectively managed, which is propelling market growth through 2035.]]></description>
   <link>https://industrytoday.co.uk/health_and_safety/global-pouchitis-market-to-reach-new-heights-by-2035-bis-research</link>
   <guid isPermaLink="false">https://industrytoday.co.uk/health_and_safety/global-pouchitis-market-to-reach-new-heights-by-2035-bis-research</guid>
   <pubDate>Thu, 23 Oct 2025 18:50:47 +0000</pubDate>
  </item>
  <item>
   <title><![CDATA[Global Acute Myeloid Leukemia Market is Expanding in Precision Medicine and Targeted Therapies – BIS Research]]></title>
   <description><![CDATA[The global acute myeloid leukemia (AML) market is witnessing robust growth, fueled by innovations in diagnostics, treatment options, and a better understanding of disease biology. AML is a fast-progressing blood cancer originating in the bone marrow and spreading rapidly to the bloodstream. The rising prevalence of AML worldwide has increased demand for advanced diagnostic tools, targeted therapies, and personalized treatment approaches. Key drivers of market growth include novel chemotherapy regimens, immunotherapies, stem cell transplantation, and the development of oral formulations for improved patient convenience.]]></description>
   <link>https://industrytoday.co.uk/health_and_safety/global-acute-myeloid-leukemia-market-is-expanding-in-precision-medicine-and-targeted-therapies-bis-research</link>
   <guid isPermaLink="false">https://industrytoday.co.uk/health_and_safety/global-acute-myeloid-leukemia-market-is-expanding-in-precision-medicine-and-targeted-therapies-bis-research</guid>
   <pubDate>Thu, 23 Oct 2025 18:45:27 +0000</pubDate>
  </item>
  <item>
   <title><![CDATA[Global Tendinopathy Market is Expanding in Regenerative and Biologic Therapies – BIS Research]]></title>
   <description><![CDATA[The global tendinopathy market is witnessing significant growth, fueled by the increasing prevalence of musculoskeletal disorders, heightened awareness, and advancements in pharmacological, regenerative, and biologic therapies. Tendinopathy, characterized by pain, inflammation, and functional impairment of tendons, is a major contributor to chronic discomfort and disability worldwide, especially among athletes and individuals involved in repetitive activities. Rising incidence due to aging, sports-related injuries, and occupational hazards is driving the demand for effective treatments that provide both immediate relief and long-term management.]]></description>
   <link>https://industrytoday.co.uk/health_and_safety/global-tendinopathy-market-is-expanding-in-regenerative-and-biologic-therapies-bis-research</link>
   <guid isPermaLink="false">https://industrytoday.co.uk/health_and_safety/global-tendinopathy-market-is-expanding-in-regenerative-and-biologic-therapies-bis-research</guid>
   <pubDate>Thu, 23 Oct 2025 18:36:55 +0000</pubDate>
  </item>
  <item>
   <title><![CDATA[Global Dense Deposit Disease Market is Expanding in Complement Inhibition Therapies – BIS Research]]></title>
   <description><![CDATA[Dense deposit disease (DDD) is a rare and chronic kidney disorder characterized by the accumulation of dense deposits in the glomerular basement membrane, leading to glomerulonephritis, inflammation, and progressive kidney damage. Early diagnosis and effective treatment are critical, as DDD can ultimately result in kidney failure. Market growth is fueled by rising awareness of disease, advancements in complement system research, and development of specialized therapies targeting disease mechanisms.]]></description>
   <link>https://industrytoday.co.uk/health_and_safety/global-dense-deposit-disease-market-is-expanding-in-complement-inhibition-therapies-bis-research</link>
   <guid isPermaLink="false">https://industrytoday.co.uk/health_and_safety/global-dense-deposit-disease-market-is-expanding-in-complement-inhibition-therapies-bis-research</guid>
   <pubDate>Thu, 23 Oct 2025 18:31:03 +0000</pubDate>
  </item>
  <item>
   <title><![CDATA[Cervical Dystonia Market to Reach Significant Growth by 2035 – BIS Research]]></title>
   <description><![CDATA[The global cervical dystonia market is poised for steady expansion, with BIS Research projecting significant momentum from 2025 to 2035. This growth is attributed to the rising prevalence of cervical dystonia, ongoing advancements in neuromodulation and drug delivery technologies, and a greater focus on improved diagnostics and patient-centric treatment strategies. As healthcare systems enhance access to movement disorder specialists and broaden reimbursement policies, the market outlook remains optimistic.]]></description>
   <link>https://industrytoday.co.uk/health_and_safety/cervical-dystonia-market-to-reach-significant-growth-by-2035-bis-research</link>
   <guid isPermaLink="false">https://industrytoday.co.uk/health_and_safety/cervical-dystonia-market-to-reach-significant-growth-by-2035-bis-research</guid>
   <pubDate>Thu, 23 Oct 2025 18:25:41 +0000</pubDate>
  </item>
  <item>
   <title><![CDATA[Global Huntington’s Disease Market is Expanding in Gene and RNA-Based Therapies – BIS Research]]></title>
   <description><![CDATA[Huntington’s disease (HD) is a rare, inherited neurodegenerative disorder caused by a mutation in the HTT gene, leading to progressive breakdown of nerve cells in the brain. HD is characterized by motor dysfunction, cognitive decline, and psychiatric symptoms. The disease typically manifests in mid-adulthood and gradually worsens, causing significant disability and, in many cases, death within 10 to 30 years of diagnosis. Market growth is driven by advancements in genetic testing, novel therapies, and increasing patient awareness.]]></description>
   <link>https://industrytoday.co.uk/health_and_safety/global-huntingtons-disease-market-is-expanding-in-gene-and-rna-based-therapies-bis-research</link>
   <guid isPermaLink="false">https://industrytoday.co.uk/health_and_safety/global-huntingtons-disease-market-is-expanding-in-gene-and-rna-based-therapies-bis-research</guid>
   <pubDate>Thu, 23 Oct 2025 18:15:35 +0000</pubDate>
  </item>
  <item>
   <title><![CDATA[Metrorrhagia Market to Witness Robust Growth by 2035 – BIS Research]]></title>
   <description><![CDATA[The global metrorrhagia market is on a steady growth trajectory, with BIS Research projecting robust expansion from 2025 to 2035. Growth is fueled by the increasing burden of gynecological conditions such as uterine fibroids, polyps, hormonal imbalances, and reproductive tract infections. Innovation in both hormonal and non-hormonal therapies, as well as greater awareness and access to diagnostic tools, are driving the adoption of advanced management strategies for abnormal uterine bleeding.]]></description>
   <link>https://industrytoday.co.uk/health_and_safety/metrorrhagia-market-to-witness-robust-growth-by-2035-bis-research</link>
   <guid isPermaLink="false">https://industrytoday.co.uk/health_and_safety/metrorrhagia-market-to-witness-robust-growth-by-2035-bis-research</guid>
   <pubDate>Wed, 15 Oct 2025 11:30:50 +0000</pubDate>
  </item>
  <item>
   <title><![CDATA[Beta Thalassemia Market Set for Robust Growth through 2035 – BIS Research]]></title>
   <description><![CDATA[The global beta thalassemia market is on a steady upward trajectory, with BIS Research anticipating strong growth momentum through 2035. Market expansion is being driven by the increasing prevalence of beta thalassemia, a hereditary blood disorder, coupled with greater awareness, evolving diagnostic technologies, and the development of innovative gene-editing therapies. While blood transfusions and iron chelation remain the foundation of care, breakthroughs in gene therapy and expanded access to bone marrow transplantation are redefining treatment possibilities and improving outcomes worldwide.]]></description>
   <link>https://industrytoday.co.uk/health_and_safety/beta-thalassemia-market-set-for-robust-growth-through-2035-bis-research</link>
   <guid isPermaLink="false">https://industrytoday.co.uk/health_and_safety/beta-thalassemia-market-set-for-robust-growth-through-2035-bis-research</guid>
   <pubDate>Wed, 15 Oct 2025 11:21:55 +0000</pubDate>
  </item>
  <item>
   <title><![CDATA[Biliary Tract Cancers Market Poised for Robust Growth – BIS Research]]></title>
   <description><![CDATA[The global biliary tract cancers market is projected to witness significant expansion in the coming decade, as forecasted by BIS Research. Growth in this market is being propelled by a rising burden of risk factors, advances in personalized medicine, and approvals of innovative therapies tailored to genetic mutations. While challenges such as late-stage diagnosis and limited patient recruitment for clinical trials remain, technological progress and collaborative research initiatives are transforming the treatment landscape and expanding the market potential.]]></description>
   <link>https://industrytoday.co.uk/health_and_safety/biliary-tract-cancers-market-poised-for-robust-growth-bis-research</link>
   <guid isPermaLink="false">https://industrytoday.co.uk/health_and_safety/biliary-tract-cancers-market-poised-for-robust-growth-bis-research</guid>
   <pubDate>Wed, 15 Oct 2025 11:14:29 +0000</pubDate>
  </item>
  <item>
   <title><![CDATA[Microscopic Polyangiitis Market to Reach New Heights by 2035 – BIS Research]]></title>
   <description><![CDATA[The global Microscopic Polyangiitis (MPA) market is experiencing steady growth, fueled by an increasing demand for advanced pharmacological therapies that control disease activity, prevent organ damage, and enhance patient quality of life. Key therapeutic classes include corticosteroids, immunosuppressive agents, and targeted biologics such as rituximab and avacopan. Innovations in treatment, personalized medicine, and the entry of next-generation biologics and biosimilars are transforming the therapeutic landscape and driving market expansion.]]></description>
   <link>https://industrytoday.co.uk/health_and_safety/microscopic-polyangiitis-market-to-reach-new-heights-by-2035-bis-research</link>
   <guid isPermaLink="false">https://industrytoday.co.uk/health_and_safety/microscopic-polyangiitis-market-to-reach-new-heights-by-2035-bis-research</guid>
   <pubDate>Wed, 15 Oct 2025 10:59:17 +0000</pubDate>
  </item>
  <item>
   <title><![CDATA[Global Celiac Disease Market is Expanding in Diagnostics and Therapeutics – BIS Research]]></title>
   <description><![CDATA[Celiac disease, an autoimmune disorder triggered by gluten ingestion, affects millions worldwide and is becoming increasingly diagnosed across regions such as North America, Europe, and Asia-Pacific. The market is fueled by growing awareness of gluten-related disorders, the adoption of gluten-free diets, and innovations in pharmacological therapies. Advances in diagnostic technologies and enzyme-based therapies are enhancing early detection and treatment, while ongoing clinical research and novel drug development are supporting improved patient outcomes and quality of life.]]></description>
   <link>https://industrytoday.co.uk/health_and_safety/global-celiac-disease-market-is-expanding-in-diagnostics-and-therapeutics-bis-research</link>
   <guid isPermaLink="false">https://industrytoday.co.uk/health_and_safety/global-celiac-disease-market-is-expanding-in-diagnostics-and-therapeutics-bis-research</guid>
   <pubDate>Tue, 14 Oct 2025 07:49:24 +0000</pubDate>
  </item>
  <item>
   <title><![CDATA[Small Cell Lung Cancer Market to Reach New Heights by 2035 – BIS Research]]></title>
   <description><![CDATA[According to BIS Research, the global small cell lung cancer (SCLC) market is experiencing dynamic growth, fueled by rising cancer incidence, increasing awareness, and major progress in both immunotherapy and targeted drug development. The market is being shaped by the need for improved patient outcomes, particularly for vulnerable populations such as older adults and smokers, and is projected to grow steadily over the coming decade as new therapies and diagnostic innovations become more widely accessible.]]></description>
   <link>https://industrytoday.co.uk/health_and_safety/small-cell-lung-cancer-market-to-reach-new-heights-by-2035-bis-research</link>
   <guid isPermaLink="false">https://industrytoday.co.uk/health_and_safety/small-cell-lung-cancer-market-to-reach-new-heights-by-2035-bis-research</guid>
   <pubDate>Tue, 14 Oct 2025 07:38:34 +0000</pubDate>
  </item>
  <item>
   <title><![CDATA[Geographic Atrophy Market to Witness Robust Growth by 2035 – BIS Research]]></title>
   <description><![CDATA[The global geographic atrophy market is projected to experience substantial growth between 2025 and 2035. This momentum is driven by technological innovations in retinal therapies, including gene therapies, biologics, and stem cell approaches. The demand for effective management of geographic atrophy a major cause of vision impairment among the elderly continues to climb as the global population ages and awareness of AMD rises. Investment in healthcare infrastructure, particularly in North America and Europe, and the proliferation of advanced diagnostic tools, are supporting rapid market development. Despite notable challenges such as high treatment costs and regulatory hurdles, ongoing research and the entry of new therapies are expected to support the market’s positive outlook.]]></description>
   <link>https://industrytoday.co.uk/health_and_safety/geographic-atrophy-market-to-witness-robust-growth-by-2035-bis-research</link>
   <guid isPermaLink="false">https://industrytoday.co.uk/health_and_safety/geographic-atrophy-market-to-witness-robust-growth-by-2035-bis-research</guid>
   <pubDate>Tue, 14 Oct 2025 07:30:01 +0000</pubDate>
  </item>
  <item>
   <title><![CDATA[Hemophilia B Market to Reach Significant Growth by 2035 – BIS Research]]></title>
   <description><![CDATA[According to BIS Research, the global hemophilia B market is set for robust expansion through 2035. This growth is underpinned by major advances in gene therapies such as Hemgenix and Beqvez, as well as long-acting factor IX replacement therapies. These innovations are transforming patient outcomes, offering the potential for functional cures and long-term reductions in bleeding events. Enhanced early detection methods and broader insurance coverage are further accelerating adoption, though challenges around affordability and long-term safety remain key considerations.]]></description>
   <link>https://industrytoday.co.uk/health_and_safety/hemophilia-b-market-to-reach-significant-growth-by-2035-bis-research</link>
   <guid isPermaLink="false">https://industrytoday.co.uk/health_and_safety/hemophilia-b-market-to-reach-significant-growth-by-2035-bis-research</guid>
   <pubDate>Tue, 14 Oct 2025 06:43:03 +0000</pubDate>
  </item>
  <item>
   <title><![CDATA[Epidermolysis Bullosa Market to Witness Transformative Growth Driven by Advances in Gene Therapy and Regenerative Medicine – BIS Research]]></title>
   <description><![CDATA[The global epidermolysis bullosa (EB) market is on a trajectory of remarkable change, with BIS Research highlighting the impact of breakthrough therapies, advanced wound care solutions, and gene-editing technologies. Market growth is driven by heightened recognition of EB’s severity, a surge in precision medicine, and the emergence of innovative treatment modalities. As leading biopharma and biotech firms invest in research and development, the landscape for EB management is evolving—delivering new hope for patients and families affected by this rare genetic disorder.]]></description>
   <link>https://industrytoday.co.uk/health_and_safety/epidermolysis-bullosa-market-to-witness-transformative-growth-driven-by-advances-in-gene-therapy-and-regenerative-medicine-bis-research</link>
   <guid isPermaLink="false">https://industrytoday.co.uk/health_and_safety/epidermolysis-bullosa-market-to-witness-transformative-growth-driven-by-advances-in-gene-therapy-and-regenerative-medicine-bis-research</guid>
   <pubDate>Tue, 14 Oct 2025 06:16:44 +0000</pubDate>
  </item>
  <item>
   <title><![CDATA[Global Fanconi Anemia Market is Expanding in Gene Therapies – BIS Research]]></title>
   <description><![CDATA[Fanconi Anemia (FA), a rare genetic disorder affecting bone marrow and increasing susceptibility to cancers, is gaining attention due to its critical impact on blood cell production.  The market is fueled by advancements in gene therapy, stem cell treatments, and growing investments in healthcare infrastructure as per BIS Research. Despite the challenges of high treatment costs and complex therapeutic options, innovations in gene editing and clinical research are paving the way for more effective treatments, particularly for blood disorders and cancer.]]></description>
   <link>https://industrytoday.co.uk/health_and_safety/global-fanconi-anemia-market-is-expanding-in-gene-therapies-bis-research</link>
   <guid isPermaLink="false">https://industrytoday.co.uk/health_and_safety/global-fanconi-anemia-market-is-expanding-in-gene-therapies-bis-research</guid>
   <pubDate>Mon, 13 Oct 2025 06:04:27 +0000</pubDate>
  </item>
 </channel>
</rss>
